Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 3:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pharmacokinetic Blood Sampling Clear all
Completed No phase listed Observational

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

NCT01180075
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV), tenofovir/emtricitabine (TDF/FTC), Atazanavir (ATV), Ritonavir, Phlebotomy
Drug · Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Not applicable Interventional

McLean and Genomind Prospective Study

NCT03113890
View directory record Official record
Conditions
Major Depressive Disorder, PTSD
Interventions
Phlebotomy - Folate, Cheek Swab, Self-report surveys
Genetic · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

NCT02197247
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling - AZD9291, Rifampicin, AZD9291 tablet dosing, Pharmacokinetic sampling - rifampicin, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

NCT01048879
View directory record Official record
Conditions
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Interventions
pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)

NCT00571961
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra (lopinavir/ritonavir), buprenorphine, Clinical evaluations/Blood draws
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT02161770
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

NCT03197961
View directory record Official record
Conditions
HIV/AIDS, Contraception
Interventions
tenofovir/emtricitabine, DMPA
Combination Product · Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

NCT00647868
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

NCT00049517
View directory record Official record
Conditions
Leukemia
Interventions
sargramostim, busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (GO), Daunorubicin, Autologous HCT, Allogeneic HCT
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
16 Years to 60 Years
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
98
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects

NCT03396250
View directory record Official record
Conditions
Pain
Interventions
Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)

NCT04331288
View directory record Official record
Conditions
Potential Treatment for Alcohol Dependence-Alcohol Interaction
Interventions
PT150, Beverage
Drug · Other
Lead sponsor
Pop Test Oncology LLC
Industry
Eligibility
21 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 13, 2026, 3:18 PM EDT
Not listed Phase 4 Interventional

Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol

NCT04049786
View directory record Official record
Conditions
Obesity, Bariatric Surgery, Roux-en Y Gastric Bypass
Interventions
Digestive biopsy, Carvedilol 25mg, Serial blood sampling for PK analysis, Metoprolol 100 mg for CYP2D6 phenotyping, Simvastatin 40mg, Midazolam 2 mg for CYP3A4 phenotyping, Genotyping
Procedure · Drug · Other
Lead sponsor
Natalia Valadares de Moraes
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

NCT01027364
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
Factor IX (rFIXFc), rFIX
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 13, 2026, 3:18 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447
View directory record Official record
Conditions
Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Not applicable Interventional

Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients

NCT01419678
View directory record Official record
Conditions
Lung Transplant Infection, Fungal Infection
Interventions
collection of blood samples for PK testing
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 2 Interventional Results available

A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine

NCT02209181
View directory record Official record
Conditions
Pain
Interventions
JNJ-10450232 / Not yet marketed, acetaminophen / Tylenol
Drug
Lead sponsor
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 13, 2026, 3:18 PM EDT
Active, not recruiting Early Phase 1 Interventional

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

NCT01269593
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Myeloma, Active Solid Malignancy
Interventions
PET Imaging using 124 IPUH71
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

NCT02311946
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Alone, Palbociclib + Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Miami, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions

NCT03424135
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

NCT02224053
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

NCT00877370
View directory record Official record
Conditions
Acute Kidney Failure
Interventions
ertapenem
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

NCT02197234
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing, Pharmacokinetic sampling - simvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 13, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling, AZD9291, Itraconazole
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 13, 2026, 3:18 PM EDT